로딩 중…
지수 로딩 중…
Maze Therapeutics, Inc.
MAZE· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$27.33+1.52%
2026-08-03
Financials
Valuation Metrics
Maze Therapeutics, Inc.'s Market Cap is $1.51B. At end of 2025 it was $1.78B. Ranked #2240 of 3,112 in US market (top 72%), #890 of 1,445 on NASDAQ (top 62%), #163 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 61%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.51B | US#2,240/3,112 Sec#163/269 |
| Revenue | $20M | US#2,904/3,112 Sec#173/269 |
| Net Income | $-123M | US—/3,112 Sec—/269 |
| Total Assets | $420M | US#2,808/3,112 Sec#178/269 |
| Net Assets | $342M | US#2,485/3,112 Sec#149/269 |
| Value | ||
| P/B | 4.43x | US#2,065/3,112 Sec#127/269 |
| P/S | 75.63x | US#2,897/3,112 Sec#175/269 |
| FCF Yield | -8.07% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -35.86% | US#2,664/3,112 Sec#141/269 |
| ROA | -29.20% | US#2,866/3,112 Sec#161/269 |
| Op. Margin | -670.25% | US#2,908/3,112 Sec#170/269 |
| Revenue Growth | -100.00% | US#2,948/3,112 Sec#190/269 |
| Earnings Growth | -351.04% | US#2,294/3,112 Sec#88/269 |
| Financial Health | ||
| Debt Ratio | 22.83% | US#246/3,112 Sec#82/269 |
| Total Debt | $61M | US#2,495/3,112 Sec#142/269 |
| FCF | $-122M | US#2,630/3,112 Sec#168/269 |
| Cash | $199M | US#1,736/3,112 Sec#116/269 |
| Current Ratio | 17.88x | US#141/3,112 Sec#40/269 |
| Performance | ||
| 1Y Return | 83.42% | US#421/3,112 Sec#93/269 |
| 1M Return | -12.57% | US#2,722/3,112 Sec#189/269 |
| From 52W High | -49.06% | US#2,765/3,112 Sec#216/269 |
| 1Y MDD | -54.51% | US#2,554/3,112 Sec#198/269 |
| Trading | ||
| Volume | 305,496 shares | US#2,409/3,112 Sec#235/269 |
| Trading Value | $8M | US#2,444/3,112 Sec#193/269 |
| Per Share | ||
| EPS | $-3.05 | US—/3,112 Sec—/269 |
| BPS | $8.26 | US#1,910/3,112 Sec#79/269 |